Styrylheterocycles as a novel class inhibitor of cyclooxygenase-2-mediated prostaglandin E2 production

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 9, 2004, Pages 2105-2108

  Lee, Sang Kook ^a   Park, Eun Jung ^a   Lee, Eunjung ^b   Min, Hye Young ^a   Kim, Eun Young ^b   Lee, Taeho ^b   Kim, Sanghee ^b  

^a Ewha Womans University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Cyclooxygenase 2; Prostaglandin E2; Stilbenoids; Styrylheterocycles

Indexed keywords

3 [2 (4 METHOXYPHENYL)VINYL]THIOPHENE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HETEROCYCLIC COMPOUND; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; GENE REPRESSION; INHIBITION KINETICS; MACROPHAGE; PROSTAGLANDIN SYNTHESIS;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; HETEROCYCLIC COMPOUNDS; ISOENZYMES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

MURINAE;

EID: 1842791405     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.02.038     Document Type: Article

References (15)

1. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van de Putte L.B.A., Lipsky P.E. FASEB J. 12:1998;1063-1073.
2. Vane J.R., Bakhle Y.S., Botting R.M. Annu. Rev. Pharmacol. Toxicol. 38:1998;97-120.
3. Prescott S.M., Fitzpatrick F.A. Biochim. Biophys. Acta. 1470:2000;M69-M78.
4. Smith W.L., Garavito R.M., DeWitt D.L. J. Biol. Chem. 271:1996;33157-33160.
5. Morita I. Prostag. Other Lipid Mediat. 68-69:2002;165-175.
6. For a good review with citations, see: Gusman J., Malonne H., Atassi G. Carcinogenesis. 22:2001;1111-1117.
7. Lee D., Cuendet M., Vigo J.S., Graham J.G., Cabieses F., Fong H.H.S., Pezzuto J.M., Kinghorn A.D. Org. Lett. 3:2001;2169-2171.
8. Su B.-N., Cuendet M., Hawthorne M.E., Kardono L.B.S., Riswan S., Fong H.H.S., Mehta R.G., Pezzuto J.M., Kinghorn A.D. J. Nat. Prod. 65:2002;163-169.
9. Likhitwitayawuid K., Sawasdee K., Kirtikara K. Planta Med. 68:2002;841-843.
10. Desiraju G.R., Gopalakrishnan B., Jetti R.K., Nagaraju A., Raveendra D., Sarma J.A., Sobhia M.E., Thilagavathi R. J. Med. Chem. 45:2002;4847-4857.
11. Chavatte P., Yous S., Marot C., Baurin N., Lesieur D. J. Med. Chem. 44:2001;3223-3230.
12. Kim S., Ko H., Park J.E., Jung S., Lee S.K., Chun Y.-J. J. Med. Chem. 45:2002;160-164.
13. Kim S.S., Oh O.-J., Min H.-Y., Park E.-J., Kim Y., Park H.J., Han Y.N., Lee S.K. Life Sci. 73:2003;337-348.
14. 2 level of vehicle treated-control)] × 100.
15. ′, respectively. The PCR amplification was performed under the following conditions: 38 cycles of denaturation at 94°C for 15 s, annealing at 55°C for 1 min and extension at 72°C for 1 min, using a thermal cycler (GeneAmp PCR Systems 2400; PE Applied Biosystems, USA). The amplified PCR products were run on a 2% agarose gel and visualized by SYBR Gold staining.